D
David R. Langley
Researcher at Bristol-Myers Squibb
Publications - 133
Citations - 5704
David R. Langley is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Hepatitis C virus & Integrase. The author has an hindex of 39, co-authored 132 publications receiving 5311 citations. Previous affiliations of David R. Langley include University of Texas at Austin & ViiV Healthcare.
Papers
More filters
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Patent
Hepatitis C virus inhibitors
Carol Bachand,Makonen Belema,Deon Daniel H,Andrew C. Good,Goodrich Jason,James Clint A,Lavoie Rico,Lopez Omar D,Alain Martel,Nicholas A. Meanwell,Van N. Nguyen,Jeffrey L. Romine,Ruediger Edward H,Lawrence B. Snyder,Denis R. St. Laurent,Fukang Yang,David R. Langley,Gan Wang,Lawrence G. Hamann +18 more
TL;DR: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection as mentioned in this paper, and also disclosed are pharmaceutical compositions containing such compounds and methods to use these compounds in the treatment.
Journal ArticleDOI
Selective interactions of cationic porphyrins with G-quadruplex structures.
TL;DR: This study provides the first experimental insight into how selectivity might be achieved for different G- quadruplexes by using structural variants within a single group of G-quadruplex-interactive drugs.
Journal ArticleDOI
Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Qi Guo,Hsu-Tso Ho,Ira B. Dicker,Li Fan,Nannan Zhou,Jacques Friborg,Tao Wang,Brian McAuliffe,Hwei-Gene Heidi Wang,Ronald E. Rose,Hua Fang,Helen Scarnati,David R. Langley,Nicholas A. Meanwell,Ralph Abraham,Richard J. Colonno,Pin-Fang Lin +16 more
TL;DR: Mapping of resistance substitutions to the HIV-1 envelope, and the lack of compound activity against a CD4-independent viral infection confirm the gp120-CD4 interactions as the target in infected cells and validates gp120 as a viable target for small-molecule inhibitors.
Journal ArticleDOI
Inhibition of Hepatitis B Virus Polymerase by Entecavir
David R. Langley,Ann W. Walsh,Carl J. Baldick,Betsy J. Eggers,Ronald E. Rose,Steven Levine,A. Jayne Kapur,Richard J. Colonno,Daniel J. Tenney +8 more
TL;DR: These studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients.